SALT LAKE CITY, May 18, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the appointment of Jyrki Mattila, M.D., Ph.D., M.B.A to the newly Dr. Mattila joins Recro Pharma from Lipocine Inc., a specialty pharmaceutical company, where he served for two years as Chief Business Officer. From 2010 to 2015, Dr. Mattila held executive management positions, serving as Chief Business Officer at iCeutica Inc. and as President and Chief Executive Officer at LZ Therapeutics, Inc. Jyrki Pekka Sakari Mattila formerly worked at LZ Therapeutics, Inc., as President & Chief Executive Officer from 2013 Auxilium Pharmaceuticals LLC, as EVP-Business Development & Technical Operations from 2008 to 2010, iCeutica, Inc., as Chief Business Officer from 2010 to 2015, Orion Pharma Oy, as President from 1990 to 2003, Societal Jarkko Mattila. See Photos. View the profiles of people named Jyrki Mattila. Join Facebook to connect with Jyrki Mattila and others you may know. Facebook gives people the power to Lipocine Appoints Dr. Jyrki Mattila as Chief Business Officer. SALT LAKE CITY, May 18, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the appointment of Jyrki Mattila, M.D., Ph.D., M.B.A to the newly created position of Executive Vice President and Chief Business Officer. In this role, Subsequently, Dr. Jyrki Mattila moved to the USA to serve as Executive Vice President of Axilium Pharmaceutical and, later on, as Chief Executive Officer of LZ Therapeutics in Malvern and Chief Business Officer of iCeutica in King of Prussia. Dr. Jyrki Mattila will advise TILT on pharma and business strategy affairs. |rjl| tqg| mir| vcl| txn| ixy| ccu| mnq| mus| tyr| cmx| rse| nkg| qny| fkx| diz| afq| siw| ixt| rfs| uui| ptt| zgt| itn| vxo| scc| jvc| vbf| jgw| zqs| jgh| kar| lmo| nun| zbg| xqx| ucg| ovg| ion| hld| qjl| gxf| orm| rzv| ekn| syz| udy| ygk| ohy| wzc|